PHASE 1 STUDY OF PREOPERATIVE GEMCITABINE PLUS CP-870, 893 FOLLOWED BY ADDITION OF CP-870,893 TO STANDARD -OF-CARE ADJUVANT CHEMORADIATION FOR PATIENTS WITH NEWLY DIAGNOSED RESECTABLE PANCREATIC CARCINOMA: